NCT05361031View on ClinicalTrials.gov

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

September 9, 2021

Study Completion Date

February 22, 2022

Conditions
CMT
Interventions
BIOLOGICAL

Engensis (VM202)

Intramuscular injections

Trial Locations (1)

06351

Samsung Medical Center, Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Helixmith Co., Ltd.

INDUSTRY

NCT05361031 - The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) | Biotech Hunter | Biotech Hunter